Mucinex Dm Maximum Strength: adverse event reports filed with FDA

3,328

reports as suspect product

0% of all reports · about 241 a year

177

reports, 12 months to June 2026

234 in the 12 months before

11.5%

marked serious by the reporter

33.2% across the class

0.1%

record death among outcomes, as reported

2 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Mucinex Dm Maximum Strength reports recording the termmedian drug in expectorant

1. Dizzinesslight-headedness or unsteadiness15.1%503
2. Accidental overdosean accidental overdose14.3%475
3. Drug ineffectivethe medicine did not work as expected13.2%439
4. Overdosea dose above the recommended amount9.8%327
5. Diarrhoealoose or frequent stools8.8%293
6. Nauseafeeling sick6.9%229
7. Product use in unapproved indicationused for a purpose not on the label6.4%212
8. Somnolencedrowsiness4.9%164
9. Feeling abnormalfeeling odd or not right4.3%142
10. Incorrect product administration duration4%133
11. Wrong technique in product usage processthe product was used in the wrong way3.8%126
12. Vomitingbeing sick3.6%121
13. Insomniadifficulty sleeping3.4%114
14. Inappropriate schedule of product administrationthe product was taken at the wrong times3.3%111
15. No adverse eventno adverse event was reported3.2%106
16. Headachehead pain3.1%103
17. Expired product administeredthe product was used past its expiry date3%100
18. Drug effective for unapproved indication2.9%96
19. Abdominal pain upperupper stomach pain2.8%92
20. Fatiguetiredness2.5%83
21. Incorrect drug administration duration2.5%83
22. Product size issue2.3%75
23. Dyspnoeashortness of breath2.1%70
24. Condition aggravatedthe condition being treated got worse1.9%63
25. Astheniaweakness or lack of energy1.7%57
26. Coughcough1.7%55
27. Product use complaint1.6%54
28. Anxietyanxiety1.6%52
29. Palpitationsawareness of the heartbeat1.6%52
30. Confusional stateconfusion1.5%51

Top 30 of 221 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 10 drugs in the expectorant class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 51,345 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,328 reports.

Drugs most often listed in the same reports

Other products listed in reports where Mucinex Dm Maximum Strength is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the expectorant class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Mucinex Dm Maximum Strength as a suspect or interacting product; reports listing it only as a concomitant medication (39) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.